2025.Feb.19

Corporate

Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics

The highly anticipated Healthcare Conference Taipei 2025 kicked off this Wednesday and Thursday (2/19-2/20). Dr. Heidi Wang, CEO of OBI Pharma (4174.TWO), was invited to participate in the panel discussion on " Regulatory Landscape and International Partnerships in Pharma and Diagnostics" at the Regent Taipei on 2/19.

HOMEWhat’s NewNewsInvited to the 2025 Healthcare Conference in Taipei, Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2024.Dec.31

OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal

2025.Feb.20

OBI Pharma Showcases Proprietary ADC Platform GlycOBI® in China Drawing Strong Industry Interest